XO1, a life sciences spin-out from Cambridge University, has been acquired by Janssen Pharmaceuticals, a research and development subsidiary of US-based pharmaceutical giant Johnson & Johnson (J&J).
Although neither the size nor the structure of the deal has been made public, the deal is a big win for Cambridge, J&J, and XO1’s early-stage investor Index Ventures.
Index invested at the launch of XO1, highlighted as one of Global University Venturing’s spin-outs to watch, back in 2013 in an…